Eli Lilly announces $6.5 billion six-part note offering
Eli Lilly (NYSE:LLY) has filed for a six-part note offering, with the aggregate principal amount of the notes offered ...
Eli Lilly (LLY) Expands AdvanCell Partnership for Cutting-Edge Cancer Therapies
We recently published a list of 10 Important News Updates Investors Shouldn’t Miss. In this article, we are going to take a ...
Eli Lilly & Co. stock underperforms Monday when compared to competitors
The stock's fall snapped a four-day winning streak.
Eli Lilly Seeks To Expand Into Cancer Radiopharma And Fatty Liver, With Two Global Deals
Eli Lilly strengthens its pipeline with AdvanCell for targeted alpha therapies and partners with OliX to advance OLX75016 for MASH and cardiometabolic diseases.
Eli Lilly Taps High-Grade Market to Fund Cancer Drug Purchase
Eli Lilly & Co. is tapping the US investment-grade bond market on Monday to help finance its roughly $2.5 billion purchase of ...
Eli Lilly enters global license agreement with OliX for OLX75016
OliX Pharmaceuticals announced a global licensing agreement with Eli Lilly (LLY). This collaboration focuses on the development and ...
Eli Lilly Adjusted Profit Tops Estimates as Weight-Loss Drug Sales Fall Short
Eli Lilly shares rose Thursday after the drugmaker's adjusted profit came in above estimates, offsetting weaker-than-expected revenue.